Ardelyx (ARDX) Free Cash Flow (2013 - 2026)
Ardelyx's (ARDX) quarterly Free Cash Flow came in at -$32.3 million in Q1 2026, up 16.7% YoY from -$27.7 million in Q1 2025, and down 256.9% on a QoQ basis from $20.6 million in Q4 2025.
Ardelyx (ARDX) Free Cash Flow (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Free Cash Flow data on file, last reported at -$32.3 million in Q1 2026.
- Quarterly Free Cash Flow rose 16.7% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.5 million (up 23.05% YoY) and the FY2025 annual result came in at -$44.0 million, up 4.03% from the prior year.
- Free Cash Flow slipped to -$32.3 million in Q1 2026, from $20.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $20.6 million in Q4 2025 to a low of -$44.8 million in Q1 2023.
- A 5-year average of -$16.6 million and a median of -$21.7 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow slumped 161.57% — and 2024, when it jumped 205.2%.
- Tracing ARDX's Free Cash Flow over 5 years: stood at $14.2 million in 2022, then tumbled by 161.57% to -$8.8 million in 2023, then jumped by 205.2% to $9.2 million in 2024, then soared by 123.39% to $20.6 million in 2025, then sank by 256.9% to -$32.3 million in 2026.
- The last three Free Cash Flow figures came in at -$32.3 million (Q1 2026), $20.6 million (Q4 2025), and $209000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -6.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.41 Mn |
| Jun 30, 2026 | -6.41 Mn |
| Mar 31, 2026 | -32.31 Mn |
| Mar 31, 2026 | -32.31 Mn |
| Dec 31, 2025 | 20.59 Mn |
| Dec 31, 2025 | 20.59 Mn |
| Sep 30, 2025 | 209,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | -25.99 Mn |
| Jun 30, 2025 | -25.99 Mn |
| Mar 31, 2025 | -38.78 Mn |
| Mar 31, 2025 | -38.78 Mn |
| Dec 31, 2024 | 9.22 Mn |
| Dec 31, 2024 | 9.22 Mn |
| Sep 30, 2024 | 364,000.00 |
| Sep 30, 2024 | 364,000.00 |
| Jun 30, 2024 | -19.53 Mn |
| Jun 30, 2024 | -19.53 Mn |
| Mar 31, 2024 | -35.87 Mn |
| Mar 31, 2024 | -35.87 Mn |